Cerus Corporation Common Stock (CERS)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn consistent profits, generate cash, and sell at a discount to intrinsic value. Cerus does not clear the first tests. In fiscal year 2025, ended 2025-12-31, revenue was $233.8M, but net income was -$15.6M, or diluted EPS -$0.08. In fiscal year 2024, ended 2024-12-31, revenue was $201.3M and net loss was $20.9M; in fiscal year 2023, ended 2023-12-31, revenue was $186.8M and net loss was $37.5M. Sales are growing and losses are narrowing, which is encouraging, but the company has not earned a profit in the last four years. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $57.4M and net loss was $2.9M, better than fiscal Q2 2025, the quarter ended 2025-06-30, when revenue was $52.4M and net loss was $5.7M. Still, trailing free cash flow is -$1.8M, and FairStock's FCF yield is -0.4%. The balance sheet shows debt-to-equity of 1.09, Altman Z-Score -4.71, and Piotroski F-Score 4/9—not a fortress. The INTERCEPT Blood System is proprietary, which could be a competitive advantage, but the financials do not yet prove a durable moat. At the 2026-10-13 close of $2.26, market cap is $455.4M. FairStock calculations show P/B 6.46, P/E -75.33, EV/EBITDA 176.85, and a FairStock Score of 37/100. Those are not Graham-style bargains; they price in future success. I would want evidence of sustained positive earnings and cash flow before calling this cheap.

In plain English: Cerus sells a blood-safety system called INTERCEPT that treats donated blood to reduce pathogens. The business is growing sales but still loses money and burns a little cash, so it looks weak on profits. At $2.26 a share, the price looks expensive compared with those losses and cash flow, not cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer